ALZHEIMER'S DISEASE · White paper
Alzheimer's Disease Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About alzheimer's disease — and why its trials are hard
Alzheimer's disease is a progressive neurodegenerative disorder marked by amyloid-beta plaques, hyperphosphorylated tau neurofibrillary tangles, synaptic loss, and brain atrophy, producing memory loss, cognitive decline, and functional dependence. US prevalence is projected to approach 13 million by 2050. Alzheimer's trials are among the hardest in medicine. Cognitive endpoints such as ADAS-Cog and MMSE suffer floor and ceiling effects and are insensitive to subtle early-stage change, while composite functional/cognitive scales like CDR-Sum of Boxes and caregiver-rated ADLs are subject to rater variability. Disease progression is slow, so trials are large, long, and expensive, and heterogeneous enrollment (mixed pathologies, varied stages) dilutes signal. Biomarker endpoints, amyloid PET and CSF or blood Abeta/tau, enable earlier, more objective assessment and patient enrichment, but their correlation with clinical benefit is imperfect and imaging is costly. The recent anti-amyloid antibodies deliver statistically significant but modest slowing of decline alongside ARIA safety risks, keeping the field focused on early diagnosis, biomarker-based enrichment, and standardized rater training.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| lecanemab (Leqembi) | 2023 | early Alzheimer's (MCI or mild dementia) with confirmed amyloid (anti-amyloid monoclonal) | CLARITY-AD (Phase 3) | change in CDR-Sum of Boxes at 18 months | 27% slowing of decline vs placebo (adjusted difference -0.45 on CDR-SB); ARIA a key risk |
| donanemab (Kisunla) | 2024 | early symptomatic Alzheimer's with amyloid pathology (anti-amyloid monoclonal) | TRAILBLAZER-ALZ 2 (Phase 3) | change in integrated Alzheimer's Disease Rating Scale (iADRS) | ~35% slowing of decline on iADRS in the low/medium-tau population vs placebo; ARIA risk |
| donepezil (Aricept) | 1996 | mild, moderate, and severe Alzheimer's (acetylcholinesterase inhibitor; symptomatic) | 24/30-week pivotal study (Rogers et al.); severe-AD studies | ADAS-Cog and CIBIC-plus (mild-moderate); SIB (severe) | ADAS-Cog difference ~2.8-3.1 points vs placebo at 24 weeks; SIB difference 5.9 points in severe AD; benefit wanes after discontinuation |
| memantine (Namenda) | 2003 | moderate-to-severe Alzheimer's (NMDA receptor antagonist; symptomatic) | 28-week Phase 3 (Reisberg et al.) | SIB (cognition) and ADCS-ADL (function) | SIB difference 5.7 points and ADCS-ADL difference 3.4 points vs placebo at 28 weeks |
| rivastigmine (Exelon) | 2000 | mild-to-moderate Alzheimer's and Parkinson's disease dementia (cholinesterase inhibitor) | 24-week international patch study | ADAS-Cog and ADCS-CGIC | ADAS-Cog difference up to ~2.9 points (17.4 mg/24h patch) vs placebo, statistically significant |
| galantamine (Razadyne) | 2001 | mild-to-moderate Alzheimer's (cholinesterase inhibitor + nicotinic modulation) | US 21-week fixed-dose study | ADAS-Cog and CIBIC-plus | ADAS-Cog differences 3.3 (16 mg/day) and 3.6 (24 mg/day) points vs placebo, p<0.001 |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in alzheimer's disease development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| aducanumab (Aduhelm) — EMERGE (302) and ENGAGE (301) | conflicting Phase 3 results (EMERGE positive, ENGAGE negative); controversially approved 2021 then discontinued/withdrawn from market in 2024 | the two pivotal trials disagreed and the accelerated approval on an amyloid surrogate drew an unfavorable advisory-committee vote; Biogen ultimately pulled the drug, the archetypal Alzheimer's approval controversy |
| solanezumab (anti-amyloid, soluble) — EXPEDITION 1-3 and A4 (prevention) | failed to slow cognitive decline across symptomatic and preclinical trials | targeting soluble monomeric amyloid did not reduce plaque or change trajectory, suggesting the wrong amyloid species/target engagement |
| semagacestat (gamma-secretase inhibitor) — IDENTITY (Phase 3) | halted early; treated patients declined faster than placebo and had more skin cancers | off-target Notch inhibition and worsened cognition demonstrated the danger of broad gamma-secretase inhibition |
Choosing the right endpoint
Primary endpoints that matter in alzheimer's disease trials
- ADAS-Cog (cognitive subscale) — Long-standing cognitive endpoint, but developed for mild-moderate disease with floor/ceiling effects that limit sensitivity in preclinical and severe stages.
- CDR-Sum of Boxes (CDR-SB) — Composite cognitive-plus-functional scale used as a primary endpoint in modern anti-amyloid trials; sensitive to early change but rater-dependent.
- Amyloid PET / CSF and blood biomarkers — Enable objective diagnosis, patient enrichment, and early efficacy read-outs, but correlation with clinical benefit is imperfect and PET is expensive.
- Activities of Daily Living (ADCS-ADL) — Measures real-world functional independence central to patient value, yet relies on caregiver report and is subject to bias.
- ARIA monitoring (amyloid-related imaging abnormalities) — A critical safety endpoint for anti-amyloid antibodies (edema/microhemorrhage), requiring serial MRI and shaping benefit-risk assessment.
How iNGENū runs alzheimer's disease trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
The full white paper: approved-product analyses, pivotal endpoints and trial-design strategy. Open-access · no sign-in.
Frequently asked questions
Alzheimer's Disease clinical trials — FAQs
How much do the new anti-amyloid antibodies actually help?
Why was aducanumab so controversial?
Why are Alzheimer's trials so long and expensive?
Ready to discuss your alzheimer's disease trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal